PROSTATE CANCER
in Developing Countries.

An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, accounting for 15% of the cancers diagnosed in men. Prostate cancer is the most common cancer among men (after skin cancer), but it can often be treated successfully. The prostate gland makes fluid that forms part of semen. The prostate lies just below the bladder and surrounds the urethra. Almost all prostate cancers are adenocarcinomas, which are cancers develop from the gland cells, which make the prostate fluid. While prostate cancer often has no early symptoms, advanced prostate cancer can cause men to urinate more often or have a weaker flow of urine. Prostate cancer in its early stages usually grows very slowly and is highly curable. As a result, early diagnosis and treatment of prostate cancer before symptoms occur is of tantamount importance. Most prostate cancer–related deaths are due to advanced disease, which results from any combination of lymphatic, hematogenous, or contiguous local spread. As a result, improving early diagnosis of prostate cancer, as well as physician awareness of treatment options for late stage disease, can play a large role in reducing the burden of prostate cancer in low resource settings.

In November 2018, AHF helped convene an Electronic Consensus on prostate cancer in developing countries. The paper has been published in JCO Global Oncology as a series. Click here for the volume or click the bullet points above for the individual papers.

• Screening, Diagnosis, and Staging Tools
• Treatment of Localized Disease (Very Low Risk, Low Risk, and Intermediate Risk)
• Treatment of Localized/Locally Advanced Disease (High Risk)
• Treatment of Biochemical Recurrence Castration Sensitive Disease
• Treatment of Non-Metastatic Castration Resistant Prostate Cancer
• Treatment of Metastatic Castration Sensitive Disease
• Treatment of Metastatic Castration Resistant Disease